IDEAYA Biosciences, Inc. - 8-K Filing

IDEAYA Biosciences reports Q3 2026 results and announces NDA submission for darovasertib in metastatic uveal melanoma. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

42 articles from 2 sources · updated

Coverage